ZFIN ID: ZDB-FIG-120717-41
Kim et al., 2012 - Antagonistic Regulation of PAF1C and p-TEFb Is Required for Oligodendrocyte Differentiation. The Journal of neuroscience : the official journal of the Society for Neuroscience   32(24):8201-8207 Full text @ J. Neurosci.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Gene:
Antibodies:
Fish:
Conditions:
Anatomical Terms:
Stage Range: Protruding-mouth to Day 4
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage Range: Protruding-mouth to Day 4

Fig. 3 ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
sox10 Ab1-sox10 WT chemical treatment: drug Protruding-mouth spinal cord oligodendrocyte IHC
Ab1-sox10 Day 4 spinal cord oligodendrocyte IHC
Ab1-sox10 leo1knu6/knu6 standard conditions Protruding-mouth spinal cord oligodendrocyte IHC
Ab1-sox10 Day 4 spinal cord oligodendrocyte IHC
Ab1-sox10 leo1knu6/knu6 chemical treatment: pharmaceutical Protruding-mouth spinal cord oligodendrocyte IHC
Ab1-sox10 Day 4 spinal cord oligodendrocyte IHC
Ab1-sox10 leo1knu6/knu6 chemical treatment: drug Protruding-mouth spinal cord oligodendrocyte IHC
Ab1-sox10 Day 4 spinal cord oligodendrocyte IHC
Ab1-sox10 leo1knu6/knu6 chemical treatment: pharmaceutical Protruding-mouth spinal cord oligodendrocyte IHC
Ab1-sox10 Day 4 spinal cord oligodendrocyte IHC
Antibody Labeling Details
Antibody Assay Fish Conditions Stage Qualifier Anatomy
Ab1-elavl IHC WT chemical treatment: drug Day 4 neuron
IHC leo1knu6/knu6 standard conditions Day 4 neuron
IHC leo1knu6/knu6 chemical treatment: pharmaceutical Day 4 neuron
IHC leo1knu6/knu6 chemical treatment: drug Day 4 neuron
IHC leo1knu6/knu6 chemical treatment: pharmaceutical Day 4 neuron
Ab1-mbp IHC WT chemical treatment: drug Day 4 oligodendrocyte
IHC leo1knu6/knu6 standard conditions Day 4 Not Detected oligodendrocyte
IHC leo1knu6/knu6 chemical treatment: pharmaceutical Day 4 oligodendrocyte
IHC leo1knu6/knu6 chemical treatment: drug Day 4 oligodendrocyte
IHC leo1knu6/knu6 chemical treatment: pharmaceutical Day 4 Not Detected oligodendrocyte
Phenotype Details
Fish Conditions Stage Phenotype
WT chemical treatment: drug Protruding-mouth central nervous system myelination occurrence, normal
Protruding-mouth oligodendrocyte progenitor proliferation process quality, normal
Day 4 central nervous system myelination occurrence, normal
Day 4 oligodendrocyte differentiation process quality, normal
leo1knu6/knu6 standard conditions Protruding-mouth central nervous system myelination occurrence, abnormal
Protruding-mouth oligodendrocyte differentiation disrupted, abnormal
Protruding-mouth oligodendrocyte progenitor proliferation disrupted, abnormal
Protruding-mouth spinal cord oligodendrocyte decreased amount, abnormal
Day 4 central nervous system myelination occurrence, abnormal
Day 4 oligodendrocyte differentiation disrupted, abnormal
Day 4 oligodendrocyte progenitor proliferation disrupted, abnormal
Day 4 spinal cord oligodendrocyte decreased amount, abnormal
leo1knu6/knu6 chemical treatment: pharmaceutical Protruding-mouth central nervous system myelination occurrence, normal
Protruding-mouth oligodendrocyte differentiation process quality, normal
Protruding-mouth oligodendrocyte progenitor proliferation process quality, normal
Day 4 central nervous system myelination occurrence, normal
Day 4 oligodendrocyte differentiation process quality, normal
Day 4 oligodendrocyte progenitor proliferation process quality, normal
leo1knu6/knu6 chemical treatment: drug Protruding-mouth central nervous system myelination occurrence, normal
Protruding-mouth oligodendrocyte differentiation process quality, normal
Protruding-mouth oligodendrocyte progenitor proliferation process quality, normal
Day 4 central nervous system myelination occurrence, normal
Day 4 oligodendrocyte differentiation process quality, normal
Day 4 oligodendrocyte progenitor proliferation process quality, normal
leo1knu6/knu6 chemical treatment: pharmaceutical Protruding-mouth central nervous system myelination occurrence, abnormal
Protruding-mouth oligodendrocyte differentiation disrupted, abnormal
Protruding-mouth oligodendrocyte progenitor proliferation disrupted, abnormal
Protruding-mouth spinal cord oligodendrocyte decreased amount, abnormal
Day 4 central nervous system myelination occurrence, abnormal
Day 4 oligodendrocyte differentiation disrupted, abnormal
Day 4 oligodendrocyte progenitor proliferation disrupted, abnormal
Day 4 spinal cord oligodendrocyte decreased amount, abnormal
Full text @ J. Neurosci.